Clene Inc. (NASDAQ:CLNN) Stock Has Average Price Target of $34.00 According to Analysts

Clene Inc. (NASDAQ:CLNN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.00.

Several research analysts have weighed in on CLNN shares. Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating on shares of Clene in a research note on Monday, October 19th. Finally, Wall Street Zen raised Clene from a “sell” rating to a “hold” rating in a report on Saturday, November 7th.

Check Out Our Latest Research Report on CLNN

Institutional Trading of Clene

A hedge fund recently raised its position in Clene stock. State Street Corp raised its position in Clene Inc. (NASDAQ:CLNN – Free Report) by 27.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,901 shares of the company’s stock after acquiring an additional 8,100 shares during the quarter. State Street Corp owned approximately 0.26% of Clene worth $155,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Price Performance

Shares of NASDAQ CLNN opened at $3.52 on Thursday. The business has a 50-day moving average of $3.87 and a 200-day moving average of $5.09. The stock has a market capitalization of $50.69 million, a price-to-earnings ratio of -1.35 and a beta of 1.04. Clene has a fifty-two week low of $3.02 and a fifty-two week high of $10.84.

Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.50. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.07 million. On average, sell-side analysts expect that Clene will post -1.05 EPS for the current year.

About Clene

(Get Free Report)

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

See Also

Analyst Recommendations for Clene (NASDAQ:CLNN)

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.